All manuscripts
Publications CAR T Cells G-Rex®24 Well Plate

Cell trajectory modulation: rapid microfluidic biophysical profiling of CAR T cell functional phenotypes

Published Journal Nature Communications

Share
15 pages Cell trajectory modulation: rapid microfluidic biophysical profiling of CAR T cell functional phenotypes — Nature Communications, 2025

Overview

The Cell Trajectory Modulation (CTM) assay provides rapid, label-free profiling of CAR T cell biophysical features like size and deformability. The study compares CAR T cells manufactured in G-Rex® gas-permeable plates versus perfusion bioreactors, showing that biophysical signatures correlate with potency and phenotype.

What this paper found

A label-free microfluidic assay, the cell trajectory modulation (CTM) assay, profiles CAR T cell size and deformability within 10 minutes from 20 μL of unprocessed culture sample. In anti-CD19 CAR T cells made from three healthy donors in either G-Rex® 24-well plates or the Breez microbioreactor, 21 of 88 CTM features differed significantly between platforms. Selected features correlated with flow cytometry phenotypes, including CD127+ cells, CD4:CD8 ratio and CAR expression, and with NALM6 specific lysis at a 1:5 effector-to-target ratio. A PCA-based biophysical index separated Breez (−0.083 ± 0.74) from G-Rex® (−1.90 ± 0.46) products on the final day of manufacture.

Note: The correlation with in vitro killing assays does not establish a correlation with in vivo efficacy; the authors state that downstream validation is in progress.

CAR T cells manufactured from the same donor samples using G-Rex or Breez microbioreactor presented distinctly different biophysical signatures, with 21 out of 88 (23.9%) CTM features showing significant differences — Kerwin Kwek Zeming, Kai Yun Quek, Wei-Xiang Sin, Denise Bei Lin Teo, Ka-Wai Cheung, Chin Ren Goh, Faris Kairi, Elizabeth Lee, Francesca Lorraine Wei Inng Lim, Michaela Su-Fern Seng, Shui Yen Soh, Michael E. Birnbaum, Jongyoon Han, Nature Communications

Study details

Authors
Kerwin Kwek Zeming, Kai Yun Quek, Wei-Xiang Sin, Denise Bei Lin Teo, Ka-Wai Cheung, Chin Ren Goh, Faris Kairi, Elizabeth Lee, Francesca Lorraine Wei Inng Lim, Michaela Su-Fern Seng, Shui Yen Soh, Michael E. Birnbaum, Jongyoon Han
Institution
Critical Analytics for Manufacturing of Personalized Medicine, Singapore-MIT Alliance for Research and Technology (SMART), Singapore, Singapore · Department of Haematology, Singapore General Hospital, Singapore, Singapore · SingHealth Duke-NUS Oncology Academic Clinical Programme, SingHealth Duke-NUS Academic Medical Centre, Singapore, Singapore · SingHealth Duke-NUS Cell Therapy Centre, SingHealth Duke-NUS Academic Medical Centre, Singapore, Singapore · Department of Paediatric Hematology and Oncology, KK Women’s and Children’s Hospital, Singapore, Singapore · Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA · Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA · Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA, USA
Journal
Nature Communications
Year
2025
PMID / PMC
PMID: 40404664 · PMC
G-Rex® model(s)
G-Rex®24 Well Plate
Cell type(s)
CAR T Cells
Application area
Hematologic malignancy
Study phase
Preclinical

How G-Rex® was used

Purified T cells from three healthy donors (technical triplicates) were mixed with CD3/CD28 Dynabeads at a 1:1 cell:bead ratio and seeded into the wells of a G-Rex® 24-well plate for anti-CD19 CAR T cell manufacturing. Lentiviral vector was added one day after activation at an MOI of 5. Cells were expanded for 10 days within a 12-day process, and the final product was compared with CAR T cells made in the Breez microbioreactor using the CTM assay, flow cytometry and a potency assay.

Explore related

Full citation

Zeming KK, Quek KY, Sin WX, et al. Cell trajectory modulation: rapid microfluidic biophysical profiling of CAR T cell functional phenotypes. Nat Commun. 2025;16(1):4775.

Building a similar workflow?

Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.

Start a conversation →